Grassley seeks Commissioner
This article was originally published in The Tan Sheet
"The FDA has struggled with temporary leadership for too long," Sen. Charles Grassley (R-Iowa) asserts in a Feb. 3 letter to President Bush's Chief of Staff Andrew Card. "I reiterate my request for the President to nominate a permanent Commissioner to the FDA as soon as possible," states Grassley, who chairs the Senate Finance Committee. Grassley first called for a leader "who can be totally dedicated to the job" when NCI Director Andrew Von Eschenbach assumed the position of acting commissioner in September (1"The Tan Sheet" Oct. 3, 2005, p. 6). FDA "needs and deserves a full-time, permanent Commissioner with the authority to address the cultural, structural and scientific challenges that have plagued the agency," Grassley states. "As has been overwhelmingly evident in the past few years, there are too many concerns and questionable practices that would require anything less"...
You may also be interested in...
FDA Acting Commissioner Andrew von Eschenbach's decision to step away from day-to-day management duties at the National Cancer Institute follows a week of criticism from Capitol Hill related to his dual role
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Abingdon Health has announced that a study run in conjunction with the UK Rapid Test Consortium has demonstrated that its AbC-19 test could be an effective tool for testing vaccine efficacy.